Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comments and Opinions |

Topical Recombinant Alpha1-Antitrypsin: A Potential Treatment for Netherton Syndrome?

Juliette Mazereeuw-Hautier, MD, PhD; Judith Cope, BPharm, MSc, MRPharmS; Christina Ong, MBBS, MRCPCH; Adrian Green, RSCN, RGN, AdDip, PgDip; Alain Hovnanian, MD, PhD; John I. Harper, MD, FRCP, FRCPCH
Arch Dermatol. 2006;142(3):393-403. doi:10.1001/archderm.142.3.396.
Text Size: A A A
Published online


Netherton syndrome is a severe autosomal recessive disorder characterized by generalized scaly erythroderma, specific hair shaft defects, and atopic manifestations. Netherton syndrome is caused by mutations in SPINK5, which cause loss of expression of LEKTI (lymphoepithelial Kazal-type–related inhibitor), a serine protease inhibitor.1LEKTI could be involved in skin desquamation by its inhibitory effect on stratum corneum trypsin enzyme and stratum corneum chymotryptic enzyme. LEKTI itself would be the preferred option for replacement therapy, but it is not as yet available. Alpha1-antitrypsin (AAT) is an endogenous serine protease inhibitor used as replacement therapy in congenital AAT deficiency.2 It is a good candidate for LEKTI replacement because it inhibits pancreatic trypsin that demonstrates considerable similarities to stratum corneum trypsin enzyme and stratum corneum chymotryptic enzyme.3 To our knowledge, this is the first study to evaluate the use of topical recombinant human AAT (rAAT) gel for Netherton syndrome. The objective of the study was to evaluate the short-term efficacy and tolerability of this drug in patients with Netherton syndrome.

Figures in this Article


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption

Scoring of erythema and scaling for each patient, separately on each side and for each visit using 2 separate 10-point analogue scales (0 corresponded to the absence of lesions and 10 to the most severe skin involvement). AAT indicates alpha1-antitrypsin.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.